Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Dec 29;58(1):53.
doi: 10.3390/medicina58010053.

The Use of Targeted Monoclonal Antibodies in the Treatment of ABPA-A Case Series

Aoife O'Reilly  1   2 , Eleanor Dunican  1   2
Affiliations
Case Reports

The Use of Targeted Monoclonal Antibodies in the Treatment of ABPA-A Case Series

Aoife O'Reilly et al. Medicina (Kaunas). .

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder occurring in response to Aspergillus fumigatus that can complicate the course of asthma and cystic fibrosis. Here we present a case of acute ABPA without central bronchiectasis, a case of chronic active ABPA with central bronchiectasis, and a case of severe relapsing ABPA with central bronchiectasis. All three were initially treated with corticosteroids and antifungal agents but had an incomplete response. These patients were then treated with anti-IgE therapy with omalizumab before being switched to the anti-IL5R agent benralizumab. They responded well to both agents. These case reports highlight the potential role of omalizumab and benralizumab in the treatment of ABPA, but further studies are required to evaluate the effectiveness of these medications. Longer follow-up periods and objective measurements of the impact of treatment are necessary.

Keywords: Aspergillus fumigatus; allergic bronchopulmonary aspergillosis (ABPA); asthma; immunoglobulin E; monoclonal antibodies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Management of Case 1.
Figure 2
Figure 2
Management of Case 2.
Figure 3
Figure 3
Management of Case 3.
See this image and copyright information in PMC

References

    1. Agarwal R., Chakrabarti A., Shah A., Gupta D., Meis J., Guleria R., Moss R., Denning D., ABPA Complicating Asthma ISHAM Working Group Allergic bronchopulmonary aspergillosis: Review of literature and proposal of new diagnostic and classification criteria. Clin. Exp. Allergy. 2013;43:850–873. doi: 10.1111/cea.12141. - DOI - PubMed
    1. Agarwal R., Aggarwal A.N., Gupta D., Jindal S.K. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: Systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 2009;13:936–944. - PubMed
    1. Agarwal R., Aggarwal A.N., Dhooria S., Sehgal I.S., Garg M., Saikia B., Behera D., Chakrabarti A. A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur. Respir. J. 2015;47:490–498. doi: 10.1183/13993003.01475-2015. - DOI - PubMed
    1. Agarwal R., Dhooria S., Sehgal I.S., Aggarwal A.N., Garg M., Saikia B., Behera D., Chakrabarti A. A Randomized Trial of Itraconazole vs. Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma. Chest. 2018;153:656–664. doi: 10.1016/j.chest.2018.01.005. - DOI - PubMed
    1. Agarwal R., Muthu V., Sehgal I.S., Dhooria S., Prasad K.T., Garg M., Aggarwal A.N., Chakrabarti A. A randomised trial of prednisolone and itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur. Respir. J. 2021;58:2101787. doi: 10.1183/13993003.01787-2021. - DOI - PubMed

Publication types

MeSH terms

Substances